论文部分内容阅读
了解体外反搏治疗对脑血栓患者的疗效及作用机制。用酶联免疫吸附法（ＥＬＩＳＡ）和比色分析法分别测定了２０例脑血栓形成患者和１０例非脑血栓形成患者体外反搏前后血浆组织型纤溶酶原激活剂（ｔｉｓｓｕｅｐｌａｓｍｉｎｏｇｅｎａｃｔｉｖａｔｏｒ，ｔ－ＰＡ）和纤溶酶原激活剂抑制物（ｐｌａｓｍｉｎｏｇａｃｔｉｖａｔｏｒｉｎｈｉｂｉｔｏｒ，ＰＡＩ）活性及Ｄ－二聚体（Ｄ－ｄｉｍｅｒ）含量的变化。结果：检测到脑血栓形成患者在体外反博（ＥＣＰ）后，血浆ｔ－ＰＡ活性增高伴有Ｄ－ｄｉｍｅｒ含量增加；在非脑血栓形成患者有血浆ｔ－ｐＡ活性增高无Ｄ－ｄｉｍｅｒ含量变化。ＰＡＩ的活性于两组中均无变化。结论：体外反搏治疗后，脑血栓患者血浆中ｔ－ＰＡ水平升高，并可使纤维血块溶解。
To understand the efficacy and mechanism of EECP on patients with cerebral thrombosis. Tissue plasminogen activator (t-PA) was measured in 20 patients with cerebral thrombosis and 10 patients with non-cerebral thrombosis before and after counterpulsation by enzyme-linked immunosorbent assay (ELISA) and colorimetric analysis, respectively ) And plasminogen activator inhibitor (PAI) activity and D-dimer content were measured. Results: In patients with cerebral thrombosis, the plasma t-PA activity was increased accompanied by increased D-dimer in patients with cerebral thrombosis after anti-Bo (ECP) in vitro. There was no change in the content of D-dimer in patients with non-cerebral thrombosis . PAI activity was unchanged in both groups. CONCLUSION: After EECP treatment, plasma levels of t-PA are elevated in patients with cerebral thrombosis and fibrin clot lysis is achieved.